Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Oct 28, 2022 7:12pm
201 Views
Post# 35057166

RE:Lots to think about

RE:Lots to think about
JPkatz wrote: While we sit at near 52w lows and drift lower...What's next?   Buyout for pennies and take it private?  I shouldn't give Dan any ideas!


Share price doesn't mean anything right now - buyers are stealing the shares from those who need the cash.

What's next ?  Nothing to move the needle really.

No news release - Board said NO.
Also - doubt we'll get a 352 update as I'm thinking 352 goes obsolete.
Financials in November.
That's probably when we hear about the CITA close - 180 days is up soon.
Maybe an IBD update at that time ?
Look for details in a new presentation (that didn't make it to NR) - after financials.
Some Insiders will be buying - don't know exactly when - watch for it.

----------------

No buyout - in response to your comment - IMO.
Not going private - in response to your comment - IMO.

Animal Studies are underway.  Could be a lengthy process.
Followed by more work on Acute dosing and a Chronic plan - IMO.

----------------

That's it !
<< Previous
Bullboard Posts
Next >>